These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30576755)

  • 1. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO.
    Hanania NA; Chipps BE; Griffin NM; Yoo B; Iqbal A; Casale TB
    J Allergy Clin Immunol; 2019 Apr; 143(4):1629-1633.e2. PubMed ID: 30576755
    [No Abstract]   [Full Text] [Related]  

  • 2. Should omalizumab be used in severe asthma/COPD overlap?
    Sposato B; Scalese M; Milanese M; Masieri S; Cavaliere C; Ricci A; Paggiaro P
    J Biol Regul Homeost Agents; 2018; 32(4):755-761. PubMed ID: 30043557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [OMALIZUMAB RESCUED A ASTHMA-COPD OVERLAP SYNDROME PATIENT FROM A STATUS ASTHMATICS UNDER THE ICU MANAGEMENT].
    Gamo S; Iijima H; Seki Y; Horaguchi R; Suda Y; Shindoh Y
    Arerugi; 2016 Jul; 65(7):937-41. PubMed ID: 27545060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab treatment in asthma-COPD overlap syndrome.
    Tat TS; Cilli A
    J Asthma; 2016 Dec; 53(10):1048-50. PubMed ID: 27144514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can Xolair Be Used in Nonallergic Asthmatic?
    Ledford DK; Casale TB
    J Allergy Clin Immunol Pract; 2018; 6(6):2170. PubMed ID: 30390909
    [No Abstract]   [Full Text] [Related]  

  • 6. Improvement of exertional dyspneoa in patients with chronic obstructive pulmonary disease and severe allergic asthma responding to omalizumab.
    Pereira S; Verhille J; Cailliau E; Bonniaud P; Devouassoux G; Fry S; Guilleminault L; Khayath N; Leroyer C; Chenivesse C; Bautin N
    Clin Exp Allergy; 2023 Dec; 53(12):1298-1301. PubMed ID: 37705326
    [No Abstract]   [Full Text] [Related]  

  • 7. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.
    Chipps BE; Zeiger RS; Luskin AT; Busse WW; Trzaskoma BL; Antonova EN; Pazwash H; Limb SL; Solari PG; Griffin NM; Casale TB
    Ann Allergy Asthma Immunol; 2017 Dec; 119(6):524-532.e2. PubMed ID: 29054589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. World Asthma and COPD Forum. Clinical trial results with omalizumab.
    D'Amato G
    IDrugs; 2008 Jul; 11(7):489-92. PubMed ID: 18600594
    [No Abstract]   [Full Text] [Related]  

  • 9. Omalizumab is effective and available for treatment of patients with severe allergic asthma in Poland.
    Zastrzeżyńska W; Gawlewicz-Mroczka A; Soja J; Sładek K; Musiał J; Bazan-Socha S
    Pol Arch Intern Med; 2017 Oct; 127(10):715-717. PubMed ID: 29162793
    [No Abstract]   [Full Text] [Related]  

  • 10. Omalizumab Treatment Response in a Population With Severe Allergic Asthma and Overlapping COPD.
    Maltby S; Gibson PG; Powell H; McDonald VM
    Chest; 2017 Jan; 151(1):78-89. PubMed ID: 27742181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults.
    Fingleton J; Travers J; Williams M; Charles T; Bowles D; Strik R; Shirtcliffe P; Weatherall M; Beasley R;
    J Allergy Clin Immunol; 2015 Sep; 136(3):601-9. PubMed ID: 25746966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Patients in the IDEAL cohort: A snapshot of severe asthma in France].
    Taillé C; Pison C; Nocent C; Devouassoux G; Prud'homme A; Gruber A; Gunsoy N; Albers F
    Rev Mal Respir; 2019 Feb; 36(2):179-190. PubMed ID: 30429093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome.
    Ishiura Y; Fujimura M; Shiba Y; Ohkura N; Hara J; Kasahara K
    Pulm Pharmacol Ther; 2015 Dec; 35():28-33. PubMed ID: 26497109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab could be effective in children with severe eosinophilic non-allergic asthma.
    Bourgoin-Heck M; Amat F; Trouvé C; Bernard A; Magny JP; Lambert N; Just J
    Pediatr Allergy Immunol; 2018 Feb; 29(1):90-93. PubMed ID: 28981968
    [No Abstract]   [Full Text] [Related]  

  • 15. Challenges in the management of asthma associated with smoking-induced airway diseases.
    Thomson NC
    Expert Opin Pharmacother; 2018 Oct; 19(14):1565-1579. PubMed ID: 30196731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
    Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
    J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The challenge of diagnosing a mixed asthma-COPD phenotype (ACOS) in clinical practice.
    García-García Mdel C; Hernández-Borge J; Barrecheguren M; Miravitlles M
    Ther Adv Respir Dis; 2016 Apr; 10(2):175-8. PubMed ID: 26968234
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain.
    Vennera Mdel C; Valero A; Uría E; Forné C; Picado C
    Clin Drug Investig; 2016 Jul; 36(7):567-78. PubMed ID: 27142072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach: The Real-life Effectiveness of Omalizumab Therapy (REALITY) study.
    Singh H; Peters JI; Kaur Y; Maselli DJ; Diaz JD
    Ann Allergy Asthma Immunol; 2019 Nov; 123(5):476-482.e1. PubMed ID: 31382020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels.
    Yalcin AD; Celik B; Yalcin AN
    Immunopharmacol Immunotoxicol; 2016 Jun; 38(3):253-6. PubMed ID: 27121601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.